Artemeter-Lumefantrine therapeutic efficacy, safety and plasma levels in patients with uncomplicated falciparum malaria from the Colombian Pacific region

Tobón-Castaño, Alberto; Garcés-Murillo, Luisa; Ríos-Orrego, Alexandra; Montiel-Ramos, Jehidys; De Las Salas, Briegel; Mesa-Echeverry, Esteban; Niebles-Bolivar, Mayra.
Infectio ; 22(4): 199-205, oct.-dic. 2018. tab
Artículo en Inglés | LILACS, COLNAL | ID: biblio-953993

Documentos relacionados

  1. Antimalarial Resistance Unlikely To Explain U.K. Artemether-Lumefantrine Failures.
  2. Reply to van der Pluijm et al., "Antimalarial Resistance Unlikely To Explain U.K. Artemether-Lumefantrine Failures".
  3. Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria.
  4. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Benin.
  5. Artemether-Lumefantrine Treatment Failure in Nonimmune European Travelers With Plasmodium falciparum Malaria: Do We Need to Reconsider Dosing in Patients From Nonendemic Regions?
  6. Characterization of solid lipid dispersions prepared by hot fusion containing a double-fixed dose combination of artemether and lumefantrine.
  7. Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial.
  8. Treatment Failure in a UK Malaria Patient Harboring Genetically Variant Plasmodium falciparum From Uganda With Reduced In Vitro Susceptibility to Artemisinin and Lumefantrine.
  9. Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine.
  10. Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi.